Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4200
-0.1002 (-19.26%)
Aug 10, 2026, 10:06 AM EDT - Market open
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $961.00K in the quarter ending March 31, 2026, a decrease of -27.18%. This brings the company's revenue in the last twelve months to $4.71M, down -24.36% year-over-year. In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%.
Revenue (ttm)
$4.71M
Revenue Growth
-24.36%
P/S Ratio
1.62
Revenue / Employee
$470,788
Employees
10
Market Cap
6.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 7.06M |
| Bolt Biotherapeutics | 6.50M |
| Immuron | 4.99M |
| Xenetic Biosciences | 3.26M |
| Can-Fite BioPharma | 405.00K |
| Aprea Therapeutics | 123.30K |
ENSC News
- 4 days ago - Ensysce Biosciences completes acquisition of Cy Biopharma - TheFly
- 4 days ago - Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing - Accesswire
- 5 days ago - Ensysce Biosciences Slides: Investor presentation - Filings
- 27 days ago - Ensysce Biosciences awarded $5.3M installment in NIDA funding - TheFly
- 27 days ago - Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant - Accesswire
- 6 weeks ago - Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 - TheFly
- 6 weeks ago - Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 2 months ago - Ensysce Biosciences files to sell 1.3M shares of common stock for holders - TheFly